Striking Cancer With Its Own Weapon: Metastasizing Cells!

The 10 hallmarks of cancerinclude migration to different tissues and organs, or metastasis as this process. Cancer cells can return to the primary tumor after migrating elsewhere, as previously discovered. Recently, using these cells as carriers to deliver drugs to the primary tumor has attracted attention. In July 2018, Science Translational Medicinepublished a study that, by programming returning cancer cells with CRISPR gene editing, extended survival in mouse brain cancer models.
Cancer cells return to the primary tumor after migrating to other tissues and organs. Discovered 12 years ago, this may be one of the most surprising, unexpected developments. Self-seeding is the name of this phenomenon, which has inspired treatment strategies such as adding to these cells oncolytic (cancer-killing) viruses or suicide genes to target cancer cells at the primary tumor site.
Researchers first removed tumor cells from mice. Using CRISPR gene editing, they added molecules enabling death receptor binding. The cells could thus bind other cancer cells carrying death receptors and trigger apoptosis (programmed cell death). They were reinjected into mice with 3 tumor types: glioblastoma (GBM), recurrent glioblastoma, and breast cancer metastatic to the brain.
According to the Results;
- The treatment significantly increased mouse survival.
- Mice with primary or recurrent brain tumors showed substantial shrinkage after treatment. Of mice, 90 percent survived for months afterward.
- CRISPR-modified cells also received a drug target allowing drugs to eliminate them safely after treatment.
What Does This Study Mean for Us?
- Despite great promise, challenges remain. CRISPR-modified cancer cells attack the primary site directly, but cancer can metastasize to many organs. This treatment cannot target those other metastases.
- Another issue is that modified cancer cells could form new tumors. They remain cancer cells, after all.
- This method may be especially effective in oligometastatic cancers (with few metastases).
- It must be emphasized that these studies were performed in the laboratory and need confirmation through further analyses and clinical trials.
Sources
CRISPR-enhanced engineering of therapy-sensitive cancer cells for self-targeting of primary and metastatic tumors.
Science Translational Medicine, 11 Jul 2018.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.